TP53 and ovarian carcinoma: Future experiments will explore the efficacy of these promoters with p53-Bad* in vivo to determine the best balance between expression levels and cancer specificity for this gene therapy construct, but all three promoters show promise as ovarian cancer-specific gene therapy drivers.